Integrated multiomics analysis identifies PHLDA1+ fibroblasts as prognostic biomarkers and mediators of biological functions in pancreatic cancer
Our study presents a novel 7-gene prognostic model that significantly enhances risk stratification in PC and identifies PHLDA1+ CAFs as promising prognostic biomarkers and therapeutic targets. These findings provide new insights into the TME of PC and open avenues for personalized treatment strategies.
Authors
- Fuxiang Chen (ORCID: https://orcid.org/0000-0002-4093-2676)
- Linling Ju (ORCID: https://orcid.org/0000-0002-9541-0533)
- Weihua Cai (ORCID: https://orcid.org/0000-0001-5614-428X)
- Suqing Zhang (ORCID: https://orcid.org/0000-0001-8475-4747)
- Enyu Liu
- Yifei Jiang (ORCID: https://orcid.org/0000-0003-1818-4541)
- Guosheng Qin
- Zihan Wang (ORCID: https://orcid.org/0000-0003-2374-0215)
- Rui Wang (ORCID: https://orcid.org/0000-0003-1723-4746)
- Lin Chen (ORCID: https://orcid.org/0000-0002-6453-7996)
- Da Fu (ORCID: https://orcid.org/0000-0002-2079-6531)
Institutions
- Nantong University (CN)
- Ruijin Hospital (CN)
- Affiliated Hospital of Nantong University (CN)
- Nantong Tumor Hospital (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1592416
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00